Developments Aclarion expands use of Nociscan with Weill Cornell Medicine commercial agreement Aclarion (NASDAQ: ACON, ACONW) has announced the establishment of a second agreement with Weill Cornell Medicine to expand the use of Nociscan in a study titled “Bone Marrow Aspirate Concentrate Injection with... May 5, 2026